Skip to main content
Clinical Trials/NCT05404698
NCT05404698
Completed
Not Applicable

Integration of Multi-omics, Health Profile, Patient-related Outcomes and Exercise Data to Improve and Personalize Health Care in Hospital Settings: A CPExA Proof of Concept

Université de Sherbrooke2 sites in 1 country10 target enrollmentJune 20, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Multimorbidity - End-stage Kidney Disease
Sponsor
Université de Sherbrooke
Enrollment
10
Locations
2
Primary Endpoint
Change in perceived fatigue
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

The combination of data from different origins (biological, health, patient-related) has the potential to improve care for the elderly. Precision approaches that are emerging in health are based on the premise that a better understanding of the biological responses to interventions will make it possible to optimize the treatments. In the field of exercise, this type of approach is emerging. This pilot study aims to collect preliminary data to demonstrate that a patient-centric vision with data from multiple sources is mandatory to personalize exercise intervention and improve health care. Older adults with end-stage chronic disease treated by hemodialysis represent a population of choice that requires personalized care since they are multimorbid and exhibit a complex health profile.

On the other hand, the beneficial effects of exercise are still little understood and the avoidance of adverse effects in response to exercise such as hypotension during dialysis remains uninvestigated.Objective: Demonstrate the feasibility of an integrative approach by combining "omics", clinical data, patient-related outcomes (PRO) as well as exercise variables (e.g., intensity, duration) Methods: A total of 10 people aged 60 and over will be recruited to randomly perform 2 experimental conditions: hemodialysis alone (CONT) or hemodialysis + aerobic exercise (EX), which will be carried out over 2 visits one week apart. These visits will take place at the scheduled time of the hemodialysis treatment. The variables of interest are: blood pressure response to a single bout of exercise exercise (during and post-exercise), symptoms (with visual analogue scales within 36 hours of the visit + Dialysis symptom index for the 7 days after the experimental visit), dialysis efficiency (Kt/V) and biological response (proteomics and metabolomics). Health-related quality of life (KDQOL questionnaire), medical data (electronic medical record), and level of physical activity (PASE questionnaire and smart watch; Apple Watch) will be evaluated.

Registry
clinicaltrials.gov
Start Date
June 20, 2022
End Date
September 15, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • being treated by hemodialysis for end-stage kidney disease for at least 3 months
  • medically eligible

Exclusion Criteria

  • diagnosed neurocognitive decline
  • hip fracture with recent hemiarthroplasty preventing hip flexion while pedalling,
  • COVID-19 positive,
  • already included in another study.

Outcomes

Primary Outcomes

Change in perceived fatigue

Time Frame: Measured at 2:00 pm and 6:00 pm the day of the experimental condition and at 10:00 am, 2:00 pm and 6:00 pm the day following the experimental condition (for a total of 24 hours).

10-centimeter horizontal visual analog scale, going from no fatigue (left) to extreme fatigue (right)

Plasma Metabolome and proteome at the end of the control (rest) condition

Time Frame: After 30 minutes of rest

A blood draw will be realized immediately at the end of the dialysis session representing the control condition. The plasma metabolome and proteome will be determined using mass spectrometry.

Change in mood

Time Frame: Measured at 2:00 pm and 6:00 pm the day of the experimental condition and at 10:00 am, 2:00 pm and 6:00 pm the day following the experimental condition (for a total of 24 hours).

10-centimeter horizontal visual analog scale, going from very bad (left) to very good (right)

Change in perceived soreness

Time Frame: Measured at 2:00 pm and 6:00 pm the day of the experimental condition and at 10:00 am, 2:00 pm and 6:00 pm the day following the experimental condition (for a total of 24 hours).

10-centimeter horizontal visual analog scale, going from no soreness (left) to extreme soreness (right)

Change in perceived sleepiness

Time Frame: Measured at 2:00 pm and 6:00 pm the day of the experimental condition and at 10:00 am, 2:00 pm and 6:00 pm the day following the experimental condition (for a total of 24 hours).

10-centimeter horizontal visual analog scale, going from no sleepiness (left) to extreme sleepiness (right)

Plasma Metabolome and proteome at the end of the experimental (exercise) condition

Time Frame: After 30 minutes of exercise

A blood draw will be realized immediately at the end of the dialysis session comprising the exercise condition. The plasma metabolome and proteome will be determined using mass spectrometry.

Change in blood pressure

Time Frame: Before and after the condition as well as every 5 minutes during the 20 minutes after (10 measurements). After this time frame, each 30 minutes up to the end of the dialysis session.

Measured using standard clinical procedures (Automatic Blood Pressure Monitor at rest and with aneroid sphygmomanometer during and after exercise)

Change in perceived sleep quality

Time Frame: Measured at 10:00 am the day following the experimental condition.

10-centimeter horizontal visual analog scale, going from very bad (left) to extreme soreness (right)

Single pool Kt/V, experimental (exercise) condition

Time Frame: After 4 hours of dialysis

measured using standard clinical procedures (blood draw before and at the end of the dialysis session comprising the exercise condition, by a research nurse).

Single pool Kt/V, control (rest) condition

Time Frame: After 4 hours of dialysis

measured using standard clinical procedures (blood draw before and at the end of the dialysis session representing the condition, by a research nurse).

Secondary Outcomes

  • White blood cells count (10^9/L)(Extracted from each patient's medical record at inclusion.)
  • Platelets count (10^9/L)(Extracted from each patient's medical record at inclusion.)
  • Red blood cell distribution width (%)(Extracted from each patient's medical record at inclusion.)
  • Plasma potassium (mmol/L)(Extracted from each patient's medical record at inclusion.)
  • Hematocrit (%)(Extracted from each patient's medical record at inclusion.)
  • Plasma phosphate (mmol/L)(Extracted from each patient's medical record at inclusion.)
  • Physical activity scale for the Elderly (PASE) questionnaire(Once, at the beginning of the dialysis session comprising the first condition)
  • Hemoglobin (g/L)(Extracted from each patient's medical record at inclusion.)
  • Red blood cell mean corpuscular hemoglobin (pg)(Extracted from each patient's medical record at inclusion.)
  • Red blood cells count (10^12/L)(Extracted from each patient's medical record at inclusion.)
  • Red blood cell mean corpuscular volume (fL)(Extracted from each patient's medical record at inclusion.)
  • Plasma sodium (mmol/L)(Extracted from each patient's medical record at inclusion.)
  • Plasma glucose (mmol/L)(Extracted from each patient's medical record at inclusion.)
  • Plasma creatinine (mmol/L)(Extracted from each patient's medical record at inclusion.)
  • Estimated daily energy expenditure(The watch will be worn during the 24 hours following each experimental condition)
  • Plasma calcium (mmol/L)(Extracted from each patient's medical record at inclusion.)
  • Health-Related Quality of Life(Once, at the beginning of the dialysis session comprising the first condition)
  • Disease-related symptoms(Twice, seven days after each experimental conditions)

Study Sites (2)

Loading locations...

Similar Trials